$ARIA Company News Six stocks to watch 4:27 p.m. Feb. 26,

New Post Public Reply Private Reply Replies (0) Message Board

Mar 31, 2014 at 11:08 AM

$ARIA Company News

Six stocks to watch 4:27 p.m. Feb. 26, 2014 - The Trading Deck
6 stocks to watch 4:34 p.m. Feb. 12, 2014 - The Trading Deck
Ariad falls after wild ride upward, while Care.com holds on to its gains 10:02 p.m. Jan. 27, 2014 - Russ Britt
Apple green ahead of earnings; Caterpillar tops gainers 4:42 p.m. Jan. 27, 2014 - Sue Chang
Ariad shares jump nearly 30% on rumors of Big Pharma takeover 2:43 p.m. Jan. 24, 2014 - Russ Britt
5 charts to watch 4:52 p.m. Jan. 15, 2014 - The Trading Deck
Apple closes lower; B. of A. rises on analyst call 5:15 p.m. Jan. 2, 2014 - Wallace Witkowski
Apple gains on China Mobile deal; homebuilders rally 4:33 p.m. Dec. 23, 2013 - Wallace Witkowski
Suspension is lifted for Ariad's leukemia drug 7:33 a.m. Dec. 23, 2013 - MarketWatch.com
J.C. Penney and more of the year's most profitable shorts 4:23 p.m. Dec. 9, 2013 - blogs.marketwatch.com
Hewlett-Packard, a cyclical green light and why silver is in trouble 9:50 a.m. Nov. 26, 2013 - Shawn Langlois
Ariad takes another pounding after leukemia treatment is pulled 1:14 p.m. Oct. 31, 2013 - Russ Britt
H-P has best day in four months on upbeat outlook 4:34 p.m. Oct. 9, 2013 - Sue Chang
Ariad plummets 70% after drug test patients have serious clotting issues 11:38 a.m. Oct. 9, 2013 - Russ Britt
FDA places partial hold on Ariad's Iclusig trials 8:16 a.m. Oct. 9, 2013 - MarketWatch.com
Dan Loeb makes bet on Disney 8:06 p.m. Aug. 14, 2013 - David Benoit
Onyx share surge lifts several boats in biotech harbor, including ETFs 11:33 a.m. July 1, 2013 - Russ Britt
SAC Capital Advisors likes this pharma stock 4:24 p.m. April 18, 2013 - Insider Monkey
Ariad Pharma up 6% to $20.09 11:35 a.m. Dec. 17, 2012 - Steve Gelsi
FDA OKs Iclusig to treat rare types of leukemia 2:06 p.m. Dec. 14, 2012 - MarketWatch.com

Mid-Day Market Update: Restoration Hardware Surges On Earnings; Endocyte Shares Drop 11:23 a.m. March 28, 2014 - benzinga.com
Mid-Day Market Update: Restoration Hardware Surges On Earnings; Endocyte Shares Drop 11:23 a.m. March 28, 2014 - benzinga.com
Mid-Morning Market Update: Markets Open Higher; BlackBerry Reports Smaller-Than-Expected Loss 9:22 a.m. March 28, 2014 - benzinga.com
Biggest Movers in Healthcare Stocks Now – MNKD ARIA CYH HALO 9:00 a.m. March 28, 2014 - InvestorPlace.com
Aria up premarket on buyout rumors 7:35 a.m. March 28, 2014 - Seeking Alpha
ARIA Stock Gets Big Boost From JAZZ Buyout Rumors 7:20 a.m. March 28, 2014 - InvestorPlace.com
Benzinga's Top #PreMarket Gainers 7:08 a.m. March 28, 2014 - benzinga.com
Novartis lung-cancer drug produces response in over half of patients 4:26 a.m. March 27, 2014 - Seeking Alpha
ARIAD Candidate in Phase II Study - Analyst Blog 6:10 p.m. March 26, 2014 - Zacks.com
Novartis Drug Shows Promise in Rare Lung Cancer 5:20 p.m. March 26, 2014 - The Wall Street Journal Interactive Edition
Novartis Targeted Lung Cancer Drug Highlighted in This Week's NEJM 5:14 p.m. March 26, 2014 - TheStreet.com
Large Cap Biopharmaceuticals Are Core Holdings After Sell-Off: AbbVie, Amgen, Gilead 8:12 a.m. March 26, 2014 - Seeking Alpha
Cramer's Mad Money - The 'What, Me Worry?' HMOs (3/25/14) 6:22 a.m. March 26, 2014 - Seeking Alpha
Morning Market Movers 8:39 a.m. March 25, 2014 - benzinga.com
Why Now Is The Time To Buy Ariad Pharmaceuticals 3:20 p.m. March 24, 2014 - Seeking Alpha
Looking For Value Among Biotechs After Precipitous Declines In Stock Price 12:26 p.m. March 24, 2014 - Seeking Alpha
Cramer's Mad Money - Which IPOs To Watch, Which IPOs To Ignore (3/17/14) 6:15 a.m. March 18, 2014 - Seeking Alpha
Perilous Reversal Watch: Ariad Pharmaceuticals (ARIA) 3:03 p.m. March 17, 2014 - TheStreet.com
Biotech Stock Roundup: InterMune Grabs Headlines with Impressive Data - Analyst Blog 10:58 a.m. March 5, 2014 - Zacks.com
ARIAD Pharmaceuticals' CEO Presents at Cowen and Company 34th Annual Health Care Conference (Transcript) 2:01 p.m. March 4, 2014 - Seeking Alpha

Newmont Mining Corp Denies Cutting Output; Indonesian Copper and Gold Mine and Ford Raised CEO Alan Mulally's Compensation by 11% 12:16 a.m. Today - ACCESSWIRE
Insider Trading Research -- Alerts for Ariad Pharmaceuticals, Cell Therapeutics, Staples, Sirius XM, Facebook, and Bank of America 8:55 a.m. March 25, 2014 - PR Newswire - PRF
ARIAD Announces Initiation of Pivotal Phase 2 ALTA Trial of AP26113 in Patients with Non-Small Cell Lung Cancer 7:35 a.m. March 24, 2014 - BusinessWire - BZX
Financial Results, Clinical Study Updates, Clinical Trial Results, Business Spin-Offs, and New Joint Ventures - Analyst Notes on ARIAD, NewLink, Puma Biotechnology, Theravance, and Ohr Pharmaceutical 8:00 a.m. March 12, 2014 - PR Newswire - PRF
Most Active Equities Technical Snapshot: SandRidge Energy, Ariad Pharma, Groupon, and Vodafone 10:12 a.m. March 11, 2014 - PR Newswire - PRF
New Appointments, Contract Extensions, Share Price Movements, Conference Schedules, and Closing of Public Offerings - Analyst Notes on Ariad, Novavax, Fonar, bluebird, and Cara 7:24 a.m. March 5, 2014 - PR Newswire - PRF
Workday Upgraded to $150 a Share; Ariad Pharmaceuticals Q4 Loss Widens 12:34 a.m. Feb. 28, 2014 - ACCESSWIRE
ARIAD Reports 2013 Financial Results and Outlines Key Objectives for 2014 7:35 a.m. Feb. 25, 2014 - BusinessWire - BZX
ARIAD to Present at the Cowen and Company 34th Annual Health Care Conference 7:35 a.m. Feb. 24, 2014 - BusinessWire - BZX
ARIAD Expands Its Board of Directors with Appointment of Alexander J. Denner, Ph.D. of Sarissa Capital Management 7:35 a.m. Feb. 21, 2014 - BusinessWire - BZX
Facebook to Buy Messaging App WhatsApp; Garmin Ltd. Hits New 1-year High on Earnings 12:29 a.m. Feb. 20, 2014 - ACCESSWIRE
ARIAD to Present at the RBC Capital Markets Healthcare Conference 7:35 a.m. Feb. 19, 2014 - BusinessWire - BZX
ARIAD to Host Conference Call and Webcast Discussion of Fourth Quarter and Year-End 2013 Financial Results on February 25, 2014 7:35 a.m. Feb. 10, 2014 - BusinessWire - BZX
TrendingWallStreet.com Announces Coverage on DDD, ARIA, ENIP, and LATF 12:24 a.m. Feb. 6, 2014 - ACCESSWIRE
ARIAD to Present at the Leerink Swann Global Healthcare Conference 7:35 a.m. Feb. 5, 2014 - BusinessWire - BZX
ARIAD Announces Commercial Agreement for Iclusig (Ponatinib) in Australia 7:35 a.m. Jan. 28, 2014 - BusinessWire - BZX
ARIAD Announces the Commercial Availability of Iclusig (Ponatinib) for Patients with Refractory Philadelphia-Positive Leukemias in the U.S. 7:35 a.m. Jan. 17, 2014 - BusinessWire - BZX
Divestiture, Service Deployment, Executive Promotion, Updated Outlook, and Designation Granted-Research Report on Endo, ARIAD, Align Technology, PAREXEL, and The Medicines Company 8:00 a.m. Jan. 16, 2014 - PR Newswire - PRF
ARIAD and Medinol Announce Initiation of Two Registration Trials of the NIRsupreme™ Ridaforolimus-Eluting Stent for Use in Coronary Artery Disease 7:35 a.m. Jan. 14, 2014 - BusinessWire - BZX
Biologics Selected by ARIAD to Be the Exclusive Specialty Pharmacy Provider for Iclusig (ponatinib) 7:30 a.m. Jan. 13, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SmallRig Boosts Art-Driven Innovation in AI Era

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

AppLovin Legal Woes: A Deep Dive into Investor Claims

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Beko Pushes for Policy Synergy Amidst Carbon Shakeup

When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...

Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

El Pollo Loco Faces Class Action Over Wage Practices

Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...

Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...

PASCAL's Holiday Gift Edit: Timeless Watches Shine

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...